Bevacizumab Plus Standard-of-Care Treatment After Progression in Advanced Non–Small Cell Lung Cancer
This randomized clinical trial assesses the efficacy and safety of continuous bevacizumab treatment plus standard of care vs standard of care alone beyond first progression in patients with non–small cell lung cancer.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου